U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07784777) titled 'NK Cell Injection for Advanced Solid Tumors' on July 21.
Brief Summary: This is an open-label, single-arm, dose-escalation Phase I clinical study designed to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of NK Cell Injection in patients with advanced solid tumors.
Eligible participants who have signed written informed consent will be screened and, if qualified, assigned a enrollment number and sequentially assigned to the designated dose group.
The study employs a traditional "3+3" dose-escalation design. Each dose group enrolls at least 3 participants, with each participant receiving only on...